57 -9 (83) 2025 - Qudratov F.O., Bafoyeva Z.B. - THE ROLE OF GULLIAN BARRE BIOCHEMICAL MARKERS OF CSF IN EARLY DIAGNOSIS

THE ROLE OF GULLIAN BARRE BIOCHEMICAL MARKERS OF CSF IN EARLY DIAGNOSIS

Qudratov F.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Bafoyeva Z.B. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Guillain-Barré syndrome is a severe autoimmune disorder affecting the nervous system, where early diagnosis is crucial for successful treatment. Clinical features include loss of coordination, muscle weakness, and sensory disturbances. Biochemical markers, such as elevated protein levels in cerebrospinal fluid, inflammatory indicators, and antibody detection, assist in diagnosing the disease at an early stage. Early identification of these signs improves treatment outcomes and reduces the risk of complications.

Key words: Guillain-Barré, cerebrospinal fluid, gel electrophoresis (2D DIGE),matrix-assisted laser desorption/ionization time-of-flight mass spectro-metry (MALDI-TOF MS), demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN).cytokines,blood-brain barrier.

First page

355

Last page

358

For citation:Qudratov F.O., Bafoyeva Z.B. - THE ROLE OF GULLIAN BARRE BIOCHEMICAL MARKERS OF CSF IN EARLY DIAGNOSIS//New Day in Medicine 9(83)2025 355-358 https://newdayworldmedicine.com/en/new_day_medicine/9-83-2025

List of References

  1. Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P and Willison HJ: Inhibition of complement in Guillain Barré syndrome: The ICA GBS study. J Peripher Nerv Syst 1: 2017; 4-12 pp.
  2. Uncini A, Shahrizaila N and Kuwabara S: Zika virus infection and Guillain Barré syndrome: Α review focused on clinical and electrophysiological subtypes. // J Neurol Neurosurg Psychiatry 88, 2017; 266–271 pp.
  3. Hughes RA, Brassington R, Gunn AA and van Doorn PA: Corticosteroids for Guillain-Barré syndrome. // Cochrane Database Syst Rev 10: CD001446, 2016.
  4. Ding Y, Han R, Jiang W, Xiao J, Liu H, Chen X, Li X and Hao J: Programmed death ligand 1 plays a neuroprotective role in experimental autoimmune neuritis by controlling peripheral nervous system inflammation of rats. // J Immunol 197: 3831 3840, 2016.
  5. Halstead SK, Kalna G, Islam MB, Jahan I, Mohammad QD, Jacobs BC, Endtz HP, Islam Z and Willison HJ: Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes. // Neurol Neuroimmunol Neuroinflamm 3: e284, 2016.
  6. Xu L, Gao TX, Chang SH, Jiang SM, Zhang LJ, Yang L. Role of lymphocyte-related immune-inflammatory biomarkers in detecting early progression of Guillain-Barré syndrome. // J Clin Neurosci. 2022;105:31-6.
  7. Wu CL, Chao CH, Lin SW, Chien YY, Huang WY, Weng WC, et al. Case report: Plasma Biomarkers reflect immune mechanisms of Guillain–Barré syndrome. Front Neurol [Internet]. 2021 [cited 2023 Nov 15];12. Available from: https:// www.frontiersin.org/articles/10.3389/fneur.2021.720794
  8. Stettner M, Zenker J, Klingler F, Szepanowski F, Hartung HP, Mausberg AK, et al. The role of peripheral myelin protein 2 in remyelination. // Cell Mol Neurobiol 2018;38:487-96.
  9. Lim EMF, Nakanishi ST, Hoghooghi V, Eaton SEA, Palmer AL, Frederick A, et al. AlphaB-crystallin regulates remyelination after peripheral nerve injury. // Proc Natl Acad Sci 2017;114:1707–16.
  10. Baumann N., Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system // Physiol Rev 2001;81:871-927.

    file

    download